Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.
Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing ...
Fintel on MSN16h
Scotiabank Initiates Coverage of Viking Therapeutics (VKTX) with Sector Outperform RecommendationFintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...
The Brighterside of News on MSN10h
Zinc levels linked to type 2 diabetes risk, study findsScientists have uncovered a strong link between zinc levels in the human body and the risk of developing type 2 diabetes and non-alcoholic fatty liver disease. Their findings highlight the importance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback